Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,009 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cellular analysis Clear all
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00633750
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 30, 2026, 2:11 PM EDT
Completed No phase listed Observational

Adiposity and Airway Inflammation in HIV-Associated Airway Disease

NCT02975258
View directory record Official record
Conditions
Asthma, HIV, Adiposity
Interventions
Blood draw, Questionnaires, Spirometry, Methacholine challenge test, Quantitative CT scans, Urine pregnancy test, Adipose biopsy, Exhaled nitric oxide measurement
Procedure · Other · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

NCT00006243
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen, incomplete Freund's adjuvant, sargramostim, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 30, 2026, 2:11 PM EDT
Terminated No phase listed Observational

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

NCT00918658
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
biologic sample preservation procedure, immunologic technique, laboratory biomarker analysis
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Not applicable Interventional

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

NCT04134299
View directory record Official record
Conditions
To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease, Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disorders, Sickle Cell Disease
Interventions
AXA4010
Dietary Supplement
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Hollywood, Florida • Miami, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

NCT00053352
View directory record Official record
Conditions
Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Interventions
conventional surgery, cisplatin, etoposide, bleomycin sulfate, laboratory biomarker analysis
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 30, 2026, 2:11 PM EDT
Suspended Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

NCT04402788
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
411
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis

NCT00001586
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Rituximab, Fludarabine phosphate, Leukemic or stroma cells
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 30, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

NCT00126659
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
therapeutic conventional surgery, sorafenib tosylate, laboratory biomarker analysis
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

NCT06429059
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
Astaxanthin, Protandim, Melatonin, MitoQ
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

NCT03793179
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1081
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Terminated Not applicable Interventional Results available

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

NCT01108003
View directory record Official record
Conditions
Recurrent Bladder Cancer, Stage 0 Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
broccoli sprout extract, laboratory biomarker analysis, Mango Juice
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 30, 2026, 2:11 PM EDT
Terminated No phase listed Observational

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

NCT01141218
View directory record Official record
Conditions
Lung Cancer
Interventions
internet-based protocol and physician referral
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 2:11 PM EDT
Active, not recruiting Not applicable Interventional

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

NCT02178163
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
11
States / cities
Bay City, Michigan • Bloomfield Hills, Michigan • Clarkston, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Active, not recruiting Phase 3 Interventional

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02488967
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1286
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

NCT03948867
View directory record Official record
Conditions
Sickle Cell Anemia in Children
Interventions
Hydroxyurea, Elevated Arm TCD Examination, Normal Arm TCD Examination
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 16 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Phase 1 Interventional

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

NCT00005604
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interleukin-12, aldesleukin, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 30, 2026, 2:11 PM EDT
Not listed Not applicable Interventional

Cerebral Monitor Guided Therapy on Cerebral Outcomes After Cardiac Surgery

NCT03316183
View directory record Official record
Conditions
Cardiac Surgery, Protein Metabolomics, Cerebral Function, Cardiopulmonary Bypass
Interventions
Perioperative and postoperative management
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 30, 2026, 2:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394
View directory record Official record
Conditions
Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
6,035 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

NCT06874283
View directory record Official record
Conditions
Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions
Eye exam
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00085280
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 30, 2026, 2:11 PM EDT
Recruiting Phase 3 Interventional

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

NCT07383441
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration
Drug · Procedure · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
41
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 2:11 PM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 30, 2026, 2:11 PM EDT
Recruiting Phase 1 Interventional

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 2:11 PM EDT